GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kyongbo Pharmaceutical Co 214390.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

4,800

-3.90%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kyongbo Pharmaceutical Co

Its shares trade on KRX under the ticker 214390.KS. It has been listed since 29 June 2015. In the fiscal year to 31 December 2025, it reported revenue of ₩264.10bn and net income of ₩182.3m. At that date it held total assets of ₩319.54bn and shareholders' equity of ₩145.74bn.

KYONGBO PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Asan, Chungcheongnam-Do. The company went IPO on 2015-06-29. The firm distributes its products within domestic market and to overseas markets including China Japan and Europe.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Jun 2015
Employees
491

Leadership

Pay as last reported

  • Mr. Jang Han LeeChairman
  • Tae Won KangPresident, Director
  • Jeong Su ParkVice President
  • Seong Gi SonManaging Director
  • Saeng Gyu SeoManaging Director
  • Mr. Hoe Ju SonAssistant Managing Director
  • Chun Han KimAssistant Managing Director
  • Byeong Seop LeeInternal Auditor
  • Seung Ho ChoiDirector
  • Chung Ui SongNon-Executive Independent Director
  • Mr. Tae Hyeon YooNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Kyongbo Pharmaceutical employs 491 skilled workers in Asan, South Korea.
  • The company distributes pharmaceuticals across China, Japan, and Europe markets.
  • Kyongbo's domestic market presence supports stable revenue streams.

Weaknesses

  • Kyongbo's IPO in 2015 may limit recent capital for expansion.
  • The company's focus on domestic and limited international markets restricts growth potential.
  • Kyongbo's product range lacks diversity beyond core pharmaceuticals.

Opportunities

  • Expanding into new markets like Southeast Asia could boost Kyongbo's global footprint.
  • Increasing demand for pharmaceuticals in aging populations presents growth opportunities.
  • Kyongbo could leverage its Asan base for advanced manufacturing partnerships.

Threats

  • Competition from larger pharmaceutical firms in China and Europe poses a risk.
  • Regulatory changes in European markets may affect Kyongbo's distribution channels.
  • Economic downturns in key markets like Japan could reduce sales volumes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.